Burrill & Company | The 21st-century healthcare paradigm — which begins with prevention and wellness and continues to personalized medicine — has come of age. Two mega-trends, a rapidly aging global population and the emergence of new technologies, are converging to answer consumer demand for quality of life and value.

As our knowledge of genetics and molecular biology rapidly expands, a personalized approach to medical care is evolving and stands poised to revolutionize the healthcare industry. Not only does this paradigm promise to improve an individual’s treatment outcome and reduce healthcare expenditure, personalized medicine is set to transform the pharmaceutical/biotechnology and companion diagnostic markets.

We are at the threshold of significant change. However, real progress will only be realized come when clinically beneficial new products and approaches are incorporated into clinical practice.

The 7th Annual Burrill Personalized Medicine Meeting provides attendees with a detailed “window” into this personalized medicine world from where the science had led us to what hurdles need to be overcome and the policies that are required so that personalized medicine becomes part of the solution to true healthcare reform. The conference will also focus on the business and financial aspects of personalized medicine.

The agenda features leading authorities across the spectrum of personalized medicine and the meeting encourages participation, focusing on intimate discussions with small groups of panelists and expert moderators, and encourages participation from the expert audience.

As such the meeting will appeal to:

• Researchers
• Drug/Diagnostics/Tools Developers
• Payors
• Investors/Analysts
• Public Policy/Regulators